The intricate structures of the eye's posterior segment pose significant challenges for effective drug delivery in the treatment of various diseases. Current modalities, such as topical and intraocular medications, often face barriers that limit their penetration, residence time, and bioavailability. This necessitates frequent dosing, impacting patient compliance and quality of life. Suprachoroidal injection emerges as a novel and promising approach for targeted drug delivery to the posterior segment. The suprachoroidal space, situated between the sclera and choroid, provides a minimally invasive route for medication delivery, offering advantages like higher drug concentrations, increased bioavailability, and prolonged action. This method also mitigates the risk of adverse events associated with other routes, particularly corticosteroid-related complications. This review discusses the potential of suprachoroidal injection, highlighting its benefits in overcoming anatomical barriers and improving therapeutic outcomes. However, further research is crucial to address existing challenges, including technological advancements, injection techniques, and considerations of cost and accessibility. Exploring synergies with biotech products, gene therapies, and cell-based treatments can pave the way for personalized and effective strategies in managing posterior segment eye diseases.